Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. Food and Drug Administration approves Gilead Sciences Inc' s Zydelig for relapsed chronic lymphocytic leukemia, follicular lymphoma and small lymphocytic lymphoma


Wednesday, 23 Jul 2014 11:49am EDT 

Gilead Sciences Inc:Announces that the U.S. Food and Drug Administration (FDA) has approved Zydelig 150 mg tablets for the treatment of three B-cell blood cancers.Zydelig is indicated in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy and as monotherapy for patients.Accelerated approval was granted for FL and SLL based on overall response rate.Zydelig is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells. 

Company Quote

100.6
0.02 +0.02%
24 Nov 2014